<SEC-DOCUMENT>0001193125-13-277261.txt : 20130628
<SEC-HEADER>0001193125-13-277261.hdr.sgml : 20130628
<ACCEPTANCE-DATETIME>20130628161652
ACCESSION NUMBER:		0001193125-13-277261
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130625
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130628
DATE AS OF CHANGE:		20130628

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS, INC.
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16133
		FILM NUMBER:		13941115

	BUSINESS ADDRESS:	
		STREET 1:		566 QUEENSBURY AVENUE
		CITY:			QUEENSBURY
		STATE:			NY
		ZIP:			12804
		BUSINESS PHONE:		(518) 743-8892

	MAIL ADDRESS:	
		STREET 1:		566 QUEENSBURY AVENUE
		CITY:			QUEENSBURY
		STATE:			NY
		ZIP:			12804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DELCATH SYSTEMS INC
		DATE OF NAME CHANGE:	19990607
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d561582d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(d) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>OF THE SECURITIES EXCHANGE ACT OF 1934
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of report (Date of earliest event reported): June&nbsp;28, 2013 (June 25, 2013) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>DELCATH SYSTEMS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-16133</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>06-1245881</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>566 Queensbury Avenue, Queensbury, New York, 12804 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices, including zip code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(518) 743-8892 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NONE
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item 5.02(e) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delcath Systems, Inc. (the &#147;Company&#148;) announced that the Board of Directors (the &#147;Board&#148;) has promoted William Appling, age 50, to
the newly created position of Executive Vice President, Research&nbsp;&amp; Development and Global Operations. Mr.&nbsp;Appling will report directly to the Company&#146;s President and Chief Executive Officer (&#147;CEO&#148;), Eamonn P. Hobbs.
Prior to Mr.&nbsp;Appling&#146;s recent appointment as Executive Vice President, Research&nbsp;&amp; Development and Global Operations, he served as the Company&#146;s Senior Vice President, Medical Device Research and Development, a position he has
held since he joined the Company in October 2010.&nbsp;Prior to joining the Company, Mr.&nbsp;Appling spent 22 years at AngioDynamics, Inc., holding various senior level management positions including Senior Vice President, Research and Development.
Mr. Appling&#146;s current annual base salary is $256,500. Mr.&nbsp;Appling is also eligible to participate in the Company&#146;s Annual Incentive Plan with a target cash bonus equal to 40% of his annual base salary. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Concurrently with the promotion of Mr.&nbsp;Appling, the Board modified Dr.&nbsp;Krishna Kandarpa&#146;s title to Executive Vice President, Chief
Scientific Officer. Dr.&nbsp;Kandarpa will continue to report directly to the Company&#146;s President and CEO, Eamonn P. Hobbs. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company also announced that Harold Mapes, Executive Vice President, Global Operations, will be leaving the employment of the Company, effective
July&nbsp;5, 2013. It is anticipated that Mr.&nbsp;Mapes will receive certain severance payments, and will continue to serve as a consultant to the Company. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;26, 2013, the Company issued a press release announcing the above matters, a copy of which release is filed as Exhibit 99.1 to this Form 8-K and which is incorporated by reference herein.
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following exhibit is filed herewith: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of Delcath Systems, Inc., dated June 26, 2013</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD COLSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">DELCATH SYSTEMS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: June&nbsp;28, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Peter J. Graham</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peter J. Graham</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President, General Counsel</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of Delcath Systems, Inc., dated June 26, 2013</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d561582dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g561582g98l62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WILLIAM M. APPLING NAMED EXECUTIVE VICE PRESIDENT OF DELCATH SYSTEMS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Company Continues to Increase Efficiencies and Reduce Cash Utilization </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>QUEENSBURY, NY &#150; June&nbsp;26, 2013</B> <B></B>&#150;<B></B> Delcath Systems, Inc. (NASDAQ: DCTH) today announced that William M. Appling has
been promoted to the newly created position of Executive Vice President, Research&nbsp;&amp; Development and Global Operations effective immediately. Mr.&nbsp;Appling joined Delcath in October 2010 as Senior Vice President, Medical Device Research
and Development, bringing an extensive background in medical device engineering and operations management. He joins the Company&#146;s executive leadership team reporting to President and CEO Eamonn P. Hobbs. In his new role, Mr.&nbsp;Appling will
assume the duties of Harold Mapes, Executive Vice President, Global Operations, who is leaving the Company on July&nbsp;5, 2013 to pursue other opportunities, and responsibilities for Research&nbsp;&amp; Development from Krishna Kandarpa, M.D., PhD.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Kandarpa will continue to fill the important role of Executive Vice President, Chief Scientific Officer focusing on being the
clinical procedure expert, responsible for site activation including training efforts in Europe and supporting clinical trials with respect to CHEMOSAT procedures. He will continue as co-chair of Delcath&#146;s Medical Affairs Committee with
Dr.&nbsp;Gloria Lee providing expert medical advice and guidance to the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, Delcath announced that the
Company has implemented a program to further reduce its workforce in the United States by 20%. The action taken is expected to better focus the Company&#146;s organizational structure and concentrate financial resources on its clinical development
program and European commercialization of its CHEMOSAT<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Hepatic Delivery System for melphalan hydrochloride. The
Company&#146;s EU-based operations are not impacted by this realignment. As a result of the reductions and other recent measures, the Company expects cash utilization for the fourth quarter of 2013 to be approximately $6 million to $8 million.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;The actions we announced today are designed to further increase our organizational efficiencies with a goal of reducing our expected
cash burn in the fourth quarter to approximately 50% of what it was in the second quarter of 2012,&#148; said Mr. Hobbs. &#147;Our team continues to be focused on our key strategic priorities in clinical development and European
commercialization.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>About Delcath Systems</U> </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary drug/device combination product, the Delcath Hepatic Delivery
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
System, is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The
Company&#146;s initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath announced that its randomized Phase 3 clinical trial for patients with metastatic melanoma in the liver had successfully achieved the
study&#146;s primary endpoint of extended hepatic progression-free survival. The Company also completed a multi-arm Phase 2 trial to treat other liver cancers. Outside of the United States, our proprietary product to deliver and filter melphalan
hydrochloride is marketed under the trade name Delcath Hepatic CHEMOSAT<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Delivery System for melphalan
hydrochloride. The Company obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT Delivery System for Melphalan in April 2012. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT Delivery System for
Melphalan in Europe. The Company has not yet received FDA approval for commercial sale of its system in the United States. The Company&#146;s NDA has been accepted for filing and substantive review by the FDA. For more information, please visit the
Company&#146;s website at www.delcath.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking
statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may
cause such differences include, but are not limited to, uncertainties relating to: the impact of the negative advisory vote by the ODAC panel on the FDA&#146;s decision regarding the Company&#146;s new drug application (NDA), timing of completion of
the FDA&#146;s review of our NDA, the extent to which the FDA may request additional information, data, or new clinical trials and our ability to provide the same in a timely manner, additional extensions to the PDUFA date by the FDA, acceptability
of the Phase 1, 2 and 3 clinical trial data by the FDA, FDA approval of the Company&#146;s NDA for the treatment of ocular metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, adoption, use and resulting
sales, if any, for the CHEMOSAT system to deliver and filter melphalan in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with primary and
metastatic disease in the liver, market acceptance of the Gen Two CHEMOSAT system and patient outcomes using the same, approval of the current or future chemosaturation system for delivery and filtration of melphalan, doxorubicin or other
chemotherapeutic agents for various indications in the US and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, our ability to successfully enter into strategic partnership and distribution arrangements in foreign
markets including Australia and key Asian markets and timing and revenue, if any, of the same, the approval of the Hepatic CHEMOSAT Delivery System device to deliver and filter doxorubicin in key Asian markets and patient outcomes using the same,
our ability to obtain reimbursement for the CHEMOSAT system, uncertainties relating to the timing and results of research and development projects, uncertainties relating to the timing and results of future clinical trials, and uncertainties
regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You
should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the
date they are made. </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Contact Information:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investors:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial Media</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory Gin/Patty Eisenhaur</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chris Gale</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVC Group</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVC Group</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">646-445-4801/951-316-0577</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">646-201-5431</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>###</I> </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g561582g98l62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g561582g98l62.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`30$#`P$1``(1`0,1`?_$`,$````&`@,!````````
M```````&!P@)"@$$`@,%"P$``00#`0````````````````,$!0<!`@8($```
M!0,#`@0$!`(&!PD!```!`@,$!1$&!P`2""$3,2(4"4%1%0IA,B,6<4*!D5(S
M)!>A<H*24T0EL<'Q0W.C-#9'&!$``0,"!`,#"00(`P<%`````0`"`Q$$(1(%
M!C%!46$3!W&!D;'1(C)2%*'!0A7PX6*RTB,S)'*"LY*B4W/#-"5#DQ8V"/_:
M``P#`0`"$0,1`#\`OB7))&B(*>ETRD46BXB8D6S<]2^H-'1[AR1)6H^5$ZJ(
M`)M)_E,4UTUQ)XBN)YX)H;]\-J]SA@`ZGF5(R9^Z<Y71%Q7)$$XT8"6;P-QS
M<(BNYN>_RN%T(F3=,$EG!6R?IRKJD;@8X)^0#".WI37HG3?!H:AIC9XWOS%@
MX5I\([*\^JIR7Q"^FU8QOI@[L^;]2TQ^ZJY:B(F+Q@X^"41Z"%UY!H(#U`:"
M7H`AJ2@\#K3*!+<O#^8QX]/A2<GB+*Z9Q:W#,>G5*!C?[J_,24XR3RWQ*L=]
M;BKT@22F/;UG&<VQC3&`%'S(MPHGC'P)$'<5(:*F\/'4?JG_`.>&:@*6]P[+
M2GX\>W"E$XC\5#:M/>L::\#AA^G:K/\`PAY\<>.>^+QR3@:Y%'`,E@:W=:,R
MA].NNRYA<@;F4_%G\X`N/0BY:IG`:E'5([GV-=;2G=I,@.6`Y&N]XYJ8GB:@
MT/-6!H>YXM:MV7+3_4;4\,/1Q3Z4A#:D`%`NPA0$@#4""4H%$H#\0*(4KKFH
M[JD64`YJ+KLONU*SO\W4HT\*_P!>F\%Q=TR-8<M>."0<Z,/J2NVH?#X^`!_X
MZ>-B+L9,$H'-?\)3;N6&6Y7`?'3-N:X&)8SDMB[&MT7O'Q$HNNWCI1_;T<L^
M;LW:[:JZ:2G;$!$O4-36@Z%%K>MV5D":/N6-P)YX*,U;4CH]B^X(JUK2>7WJ
MG#'?=0<MI1>/8(\8<#`YDWT)&(E_<]_"JDM)BFFF*:(I@S57(Y4(-1Z#6GAJ
MZ-6\(3::;=7KG/#8[>5PX\FDBIIP]"K&R\31>:A]&P"N:GX?FHKQ-L.7SZ#B
M7DHW3:OW<>P<O&K94ZK-NZ7:(JN$&9U![AFZ:IQ`-W75#&"*W8V&O`#KY%:5
MH77L0NGX8?KY(RF,`!0.OX::3.N(FU@:2GK9(P:5"ZR"4=U>E!#^G3>VN+F?
M,^9I:&4IPQJMG2QG"H7/:01_,/3\>NG+)^_J&XI/N!6N-%J/!_N]A1-U'<!1
MI3H%!'2KKNWA]VX<&UX5*V%O;7>$SJ!F(H2./D6$A,:E4SE#YB-:_AIG+%9/
M/>-)/;F*7[F"-M(W5'G0<BF3M^<I#G/L*!A/YCB4PE*%/*(B(>`]-:1SP970
M0FLCFD<:\<$V=;ESN\Y-Q]"89RE]QOAGPTE&]O\`(#-4!95UNH5*9CK-!.1D
MKJEH=SZA!J[CXB/;J"X(*S94*[@H-`^.N@VYL74[QYO+9CG@DXUH!B">/L4-
M=[OLM/D^ED(S#R=:?<N'![W"L%>X5;V0[RX]IWH\LW'-SL[0=3-U6ZZM<9EZ
M[BT9,P,F;XPK+-TB+4$_2@4^>E]8T2YT:Z$ERW^;E<"!PK7&GD2UCK,5_-WL
M6(\W#E@FZ>\;[AU]>V[@O'N4<;V#:.0IR\\F(X^7B+R?2\?&,XX\&]F3KE7A
M@%\99/T52[?*(CUZ:G=B;3&[=6^D)(<6%V%>'F47O'69+&QSCB3V=1ZU&;[9
MOOX\DN<O,C&7&RZ\"8>LVV+MC[RE)ZXK7GKS>ST:Q@+;EIA@=DVEB%8*`Z?Q
MJ:2G<'HF<PAYJ:LG?WA+'L[0)]9=*]\D62C3SS/:SI^U5<CLW>GYO>,TE],T
ME>GX0YWW*U_0!_@!Q$O\:=?ZNNO/W?O-2T&BMH!K!1<J@)@J`@-=)-O'=X(G
M#$FBU,32<_,+MT\0AHXX(6/#6I]UN"*A<##T'2!G+48+!1*&DV71(Q6:!=@:
M=,=F"PLZW0AH0AH0AH0D]R$J"5@7V[."0F0LJZU-YQ`H`1.$?FVB/4-@B'7X
M:0T^"[9>M[PFA<WKUPHD;Y\'T4A;2F1W3H:KY"=UK*J7!>CHE!5<W#=:R9"]
M2"9S<+]0ABA^4:`?H/RU[[VA<W,>B1AP%<@Y'Y6KR)K?='6GEOS']XJ_'PM]
MD#VW<J<1N-V1LB\?$9Z_;\PM8=TW1/*WA=J#MQ/W%;T?)2KY-!C)H1Z`+O7)
MS%(*8@F`@4/#7EW='B9KMCN"]M8GT8R[E:!C@`]P^<=.BO71-DV%UIEO=2#W
MI(&../&K0?D/K5?[WO\`VF+*]O>:QKE7!CF27PKDZ?DK8_:4TZ/(2ED72Q0(
M^9,$))8Y_6PTNFK0%5!WI]L=67X;;ZU;6KCZ>5U90VOXC@:`'XCC6N"Y'>&U
M+2QC+V?#PY<<>Q)/[!O(B?P;[D&)K;82#@UI9\&3Q%>L8)U4VSB1E4/66O(=
MH3=EP:-G$"@50P"8$:@`@`TU->,.C,=HYU&5H^H<W,<,:Y@.E>':HW8]V^&\
M;9L=2-GNCI2G/'[E=1]RSW0,+^VY8<+,W:V<WQE:]%7:&.<.0KPC>8NERU()
MWTH^DE0,VMN`9)&$RCMP`IFIM(`FUYUVCLZ;<%RZWAJ(Z?'QH:$T`H:U`/D5
MUZSK8TZT[P_$/:.T=54\NO[CSW,,D7.^4Q/;&,+/C"HNEV=L0V,)W)3]K$O3
M"+5Z_E&DJCO<MDDO*84DRJ!YBA0=71#X7:/93.L+IM9P035Q'$5'X13CPIBJ
MKEWZ\Q]Z'#GT\GS)8^,OW0'(BU;I9Q/+/&]DY&L9PX2:RT]C]J[Q]>]O,"+@
MG+3JL%(KR+&5(P3,/=:]YLL7:-*ZB=Q>$CV0F33FEH(_;/3]GU)SHF^S<3"-
M[JBO9_$K)W/_`#!9N3O:1Y-YEL.>1N"QK]XQW//VG-M!%--[%3D.`-1*&XXI
MJHD5%,X;C"!RFZZK'9^FW>B[_LK&X#A)'>LJ#4T.;V>M6#KE[%>[6ED-*O#@
M#YE\VW#4*YFLPX=M],-ZDME/'T.4HU-7U]V1`DZ#TZ$+3^'X:]B[MN2_:E\U
M@][Z.7_2<O-FW;5D>Y,[B:=[YOZ@7U,N6?*_$?"?`DOG/,4V>+M>VHYA'MF+
M$OJ):X;@DVWI8BW(AF4P&&0EGJ92E5H8B5!,:@==>%].V]?:UJ8$&:@PPS$#
M$8F@(Y^5>HKG5(K#3&Y*?TQ6E/E.'$=%2\S5]SGSBO.??KX3LK%F'K,%4RD3
M'W!#J7]=3=FFH9,OUM^,K%,$GQ0+^HFF0Q:C^;7HK;_A#;S6S9;YA<XC'%P^
MS+14WJ6_WQ71C:ZC0>5/XEI8.^Y,]PE;)%E6[?!\(7U`SEVVS!R:"-E/K;E2
M1\S+M6#UTV7:RS]N<Z"*XF\PDH(=`&NGVL>#VE1Z+<7UE&0^$L!H7&F8],M.
M'5/;/?+Y[A@+J@UZ?Q*Y+S^Y9EX2<1LI\F$X!C=3K'45%'A[7?2:\6VFIJ9E
MXZ#CFQY%)%ZX32(M(B(@"*ICT^`AKSCM3;QU#6#ISJT(KA7@`21PY]5;1UMH
ML>_PP]OE50A_]PQ[K&97,F3".#;,CVA=KA$MJ8KNS)3E@U7#N*$44=/X)9ZJ
MGU+O!%,I:5"NKLTW8&TK.\+-TO$<3PWNJR!E2![WQMQPIP\ZJ._W%JNH3.CT
MUQ'=BKJ5X.X?">O7S),[?^X^]SK'5TN6V1(W$5P_2G2+&<LVX\7S5I2,>]$P
M&3;*R36:<KQCYRF`E[:C=0"5J(C37;:CX2;!N=.[_2Y*OH3A*#7#L9U3;3MW
MZI9W#6W;B17G7K^TY6><0>ZFGR+]LO-7-W'5JM;5R#BC'U_+S%@W"Y/(14-?
MUGPJ<IV%U]K9T\AY-=<IT:)@.R@5^?G>?8\5EN6.S:2YKY*-XX@..&`Y4&//
MHK/;O""ZTXAA'>AN/P]*=:JAOS4YLY7Y\9FCL]9GC+-BKLC+/:62R:V.U?M8
M1G#0JTG(BX*F_4.LF\,K*F*)@\@@7K6@4]7;8VQ8Z)M]D;&\6U][$U<T$XD5
MX\%1.Y[VYNM1,S309JX5'XCTP3B.!?NX\EO;RL.Y<78,MW%$U&Y`O!C<DL_O
MYG,.W[2=<)-H(K9DI''3:%4%NF`D(8E!'7,[H\/[37K5U_E<)(@XBA(!!&8Y
M@&X\!S71[3W*;"5K9W#(13&G'SE6&?N7+Q?W-P3X5O9)%HE/7QDVWYN7634[
M*#"2?XE=RTDY9-CB*AVR+MR8H%'\I>FJH\).^M-VNCC&)#F^8!WD7>[MU"UO
M=+'.H!Y<Z%5J_;$YB6KP:Y'N>2UVQ4E<,E;F++RC[*M6/51:GNN\YXC&.:MW
M[U=-1*+BP9.5%3=`JF!@+U-KT'XG[>U?76?ELE1;2G'!WX2QWDXC`XT5.[5N
M8]+UF._'X,WVL<W[T^J[/N5O<KN"6>3%LO<&6-$'.JI&VTTQTYN9.-0,83%:
M2$N\N5BI(NBC0HG33*43C3PU7]CX(,D@S.C<2>N;R?(NMOO$@Q390[#RC^)3
M)>T7[^M^\J\]6_Q>Y56O:D'?%[(NR8YONS&JL)&S<W'H`JXMF>MQR]DU6$J_
M3W*(F(KVQ`HZKK>7AC)H5G+J$(H(1F=6OPX`TJT4I5=5MK>HU2[BM'&I>Z@X
M=O[6*M:5`QBE$:A0%"&"H`-!Z5IT'QU3RM!=AORC_`?^S0L.P:3V(MSER0EM
MMA>3DM'Q+4I#'%9\Y!(!*0!,82%,8!.(`'@%:^&EHHN\P`)*:&4CHD/><J<+
MLW)FI[N2,("-5TF;E5*E*B;H00H&I2/0KB9F<`<.&/KH@38\DIMGY+L._4"J
M6I<D;+E4+N,B@OV71^E:D;*B58`K^`:BI=)?`VKVD-Z\D]HE%K0*Z8//=8(7
M/3I80T(0T(0T(2*YV?(1F#\QR(^8([&-_.#`-!#<UMB4$24'YB/4/CI3;0FF
MU6*-[G&LK>)/S*+U<!NG28?@*^0\]<F>$<.0J51^9V8E*@)#N^\L2@AU*)#G
MJ'R'7O73&%F@QEGN^X,>'X`O*MXUKM:?F`/O']XKZTO#>.+#\1^,<:5$H%9X
M$Q(W`NP-B?;L>#`03*``!`W==>"]YWKY=RW\<<57"]F%<O,2.%:CTKU;MV)D
M6C6KG/H/IX\*X?`W!5PONH\NVFQPWQVP,W=-5KTNK)4G?$A&H'076BK3@XT4
ME73YN`F,W^NO%3D0,:E12,'\W6W_``9M+_Z_ZK*X1E@;6CN(H>E,."KSQ%N8
M/I\@>,^)XBO/MJJX?M`6K/7G[F7#V/C$5UE8+*L9>"P)M^\"5MV^CZZ7=.MH
M#VDFS),"]:`0!IX:N?QBG/Y!&W,>\;'B*XUSJL]DP2/O"\$Y2[CYDJ?OE9IG
M,S>Y?GIO,/GQX7&LC;V*K2C%B@LDRAX.`9/I`VQ4QDTDG]PS1U!```#"!1'P
M#3'PJTF!NBMDC8P3EK3FH,U27XU`KPP\BD-W7]Y]46.DD[LDX9C3\/*J.WMI
M>YKD[@%BJX(#%_"B*RY*7M<KJY[ER[)P%VRTD[`C%I&DMM!]$0CUNV8QP-C%
M!%);9O,8QB[S&TSW?M?3[RY?>:MJ<T4CZ9H_J&L`R@!IRN%1AB*^4+.W+R]B
M8(X=-AN(!P<Z`O)K6N(PXX)@_)B6R3R0SUE+.++C=>F+T,E7&O=CBP;1Q]>O
M[?AEUV:+=^,9NMU(J#AZN)E!*4H`0QA`-=SMJVVN_31;W.L2R%K:5?=1..!Y
MDJ)UF[UYE[_8Z7%$,,&6[VXT[%9JQ;-7C:WVON7F-\L)V%>,V-\67#1EPLI2
M,DV=O2-T1#.+:JM)5NU=$3$SQ0`#9L&HTKUU2FNVMA;^,6G1:9/]1;%UN<^=
MK\2YU15N&&&'$*RM.?J+]B2OU:+NKOO7^Z6N;[N7`T=CCCV*KYPK8!.<Q^)L
M0H4%R2G(7"J*A!.<3B5O>4$FL)BA4#$4`!`U?&HUU>.]*1;:O:"G]G+P_P"6
MY51M\!VX`./\W_J!62_NLLCSB5Z<1<-)NS(VHUM*\,E.&J9E!![-C*-;<9*N
M2@.Q51HFQ$4S&`1()S"'41U27@RVW#9YY8FR2F?+5PS8`,(`KVDGSJQO$>YF
MLXK>.%[FM-L"<I(J:N'*BCZ]@W@)AOF[R+R++9Y9$NBPL'VA!W`2P5GCIJTN
M2XI:2,W:GG#MU"`XM]NW*('0,`@93Q#77>+.\+[1+9L.FE\#WU`R5;2E23[K
MARY+GO#K3[359G27T4<P&)SM#N('S`\RKF-W^U+[=MWQT/'ON*.*(@(@6BT1
M(6E;Y+5E6KIFJ5RU=I2ENIQSIPJT.4IP,H8W=VU-X:\O0>*6YY!);/O+XP/+
M<S3))E=085&?%79/LK2)Y&2P001Y`?A:QO'L#<5YGN.<HN#/&K$4<SYJ%M^Z
M[:GY-I(6KAY]$QMX3-ZS%KJ,UFJD39L@N*<LQB9$J*ASK!VTEA*<?-J7VWMK
M7-RW7>:-+/#(.+V.<RG'"K`34@&G+JD=2U[1]O6_<7443Q3@6M/.O,CJJ[>2
M/N@8&UHXUN<6>&EL6G#M#!'QTG?TU'0K1(-PII&-8=D0Z*+1,A2%%,H20C7H
M8`KUM(^&6H&UGFU^]FDGC:"PR2N)X\*O97ATHJTDWMI\;W/L+.$=Y@[+$.7"
MN5RK*<BL^Y!Y19JO;D!EDT8-[Y%?'?2GT.(/`Q3=-L4S9BUC8DI%$F35%`=M
M3+G66-YS!\=>@-!VY::1MNV;'('M#B,7!Q(H#2M*D>=5IN'4YM3O08X^ZS.%
M<K2SB#T*N?\`VT>,K6O7V[<S1-[6S#W':5]9WO6*E[>FX]L_B9F*0@+=;.&3
MY@[26:O&BI5-IDSE,00$0$.NO+_C)<3LW%$S32Z![(PZL9+#B7`FK>95[['T
M:&VTAUU=-;+GBI[P#OPM/,8>55F/>FL['&.?<?S]8V*;1MBP;*MW]CQ\=:EG
MP\?"P<>J2R+;&3%O%1B#9@T]:[5446VD`5%#F,:HB(Z]!;#FN7>'L#[Z5TMT
M2SWG$N=0Q`@5./Z551[L8W\[+(AEBS\!@*9W=,%8E^W>X><:<S\))J_<R8-Q
M7DV[U,W78@PN2][1@;EFV[6$<)-T&J$E+Q[MVDV260W%3*?:!@J'AJC_`!5U
M?7K.]B@T^[NH8'Q$EL<CV-/OD8AI`.&'#@K3VAIVE2V373PPOE]W%S6D\.T=
M44ONJ7+*+Q9P\LJ/;,V#,E^W.Z8QZ!"`FT9L+6=Q:)6Y```2;M$5B@4"@!2E
M``\`UGP<?FU!TC_>N,Q]XXGX#7'BD_$R!D.E`6C1&</A&7\0Z*NA[67#-ISU
MYB6'A"X7;^/L0K&3O3)KV,54;OCVI:;-!5%BR<I`*C8)9\X;MA,6E"GZ"%`U
M?WB1N:32-#FN<[C<QY<I)QQ>P&AS`CCCV*J=C:7+?D,DJYQYNJ>3NP]%/A[Z
M_M5</.+G#6V\Z\>L>GQE=UE7U;6/WIV$Q-R*%VP%V(2'J2SR4JZ=D-)-W;`I
M@6+L,%1"M!IJB_#7Q)UR_P!R"UN;JXE@>:T+WEHHUV`&<@CGCS"LO<FV].MM
M,,WT\(D',L;7B.>4*";V@&*DK[G'#1BB<R?;S,E)53$2@3T,6^(N<-M*&,0:
M"/Q#IJ]?%J_B?M*[/=-%;8U.4#DWM5>;)(9NBT`P;WXP]*^H86A`!+<8?,)2
M@41"@$3#REIX`(AKPC),TFC.*]09A6B3C)^1HG&-I/[AF.XY6*&UA'(..VXD
MGRY13*V;&,-0*G6H_`M*ZD-/T]^H3,M6DCO'!M>F8@<:&G'BD9SFA>&UJ6FG
MH47?8RQR5NUX!3K2B95R=T5`7);EML=P>F2]*)RMW3U(M!.<M#&$/&NNS_++
M7:X_NRV4CYB'=G,-Z*"BMKJM7.<3VD^Q+]'<'9(&@*N\B)-I`2C4C.!75:@>
MG2A5980*%?P'IJ(N]Y,E?EM86MCZM;3U.HI..U?EJ3CY_8D2O?!>3<)/"W8R
M>@Y;,CBJ>Z;>.Z052*`@'_4TV_;5;`(_`GEU(Z=J]E.PME8QW^(`]>I36]BN
MF',U[AYRGI<=L^%R7''MVXEDTKTC&H+"4AP21GHZH`$FV+_Y:AOB0.H:Y;<&
MD]]5]G[L9/(TIPYA+65[DPF-3VX^LIVH>`?PU&@4%%*K.LH0T(0T(30N=%PA
M9'#+E'='=[/TG"F2GXJE-L,4REO.T@,!NE!JIXZD-ILIK=O7G,/O47JXKILM
M?D/W+Y.*/;49-1.!0,1`.R8*"!U00:N$UU*^-3@=.H_`PAKWOI\?_@(Z?\,?
MN!>5[H?^;>!\Y_>*L@P?W,W,&S<8VUC>S\,X+AFUJ6;!69!W)+?O1VY2;V_$
MMHEG(F8M)9RU/*'1:%.=,Z1&H'J`%`O35.#PDTS4=5FO[C-_-F?(:$?B=4_A
M[5V(WY?06[;&)QI&T,&)X-%.JA`Y`\C\Z\Q<P2F5,R7+-Y(RE>"B3%O%QK8'
M:R:*+DHP]LVS;K%)0T=!]T0[#5@!%"!^?XZL*PLM`V5;MCC:UH8.C?2345)I
MQY\U`7<VI[@<22YQ/:?U]5;^^WS]JR_,`*2W,GD3;CBU<DWC;+^W,46'*IG;
MS%E6?.)I+3=Q7+'JE`6<W<($].@0/.FW,(&_,.O/GBIOR+4[Q\,+O[9L@/92
MH(`]XCCQ_6K9V)MAUM:-,HI+EH>M:'LX8J&/[@KB+>>!.=5]9P/".E,1\BEH
MFZK>N?T;HT'%W0C%Q;*Z+;FI-ND9LRD3!&)NF:2]*G/N`=6!X0[DC?IPA)Q:
M&@_[_:N:WYI/=7?NC#'I^RMWVK?>O4X!XW?8+RCA<N8\3?N%_<MM/8%:-:7;
M:PS:YUW[!RK*-G(3S)Z_5,ZVB&U+?0M`#3[?_AS<[MOGZO:3F-[V@-&8`#*&
MMX4)QH>?-,-N[\.W8ORCN!((S7-E<2<Y+N(-,*]%)=>WW.MNW-,P5F\?>%Z#
MJYKBN>$MQI*Y*GX$T:169E6$<1V2'@HAB[.X,=X`E`5C`.WPU6]SX0:UH^GO
MN+FZ)H#2CQ]M6]JF[;Q)9>ZFQK;-M"16K7'KB,0I.O?IG3P'M"9/1F&C"(E[
MJ<XFC)".BT"M8YM-S5T0;F4;L42@4?3$=]PH5J80#KKE-@6[V;YL&S/=(YEX
MP5)K6CJ`5Z88+MMUW_U6@F0,R58,*$?@)Y^7[%2/]M"-))^X;PO8@)1*IR(Q
M\<P`%3F+#3B;UP4U:U()VP&'\0`=>L-_NR[:O3R^CE_TWJA-K`.W"`?^)_U&
MJT=]T%Q0OO(6/,*<I[%@):Y8_#;2X[(R:A`L%9.6AK/NA9!_#7$9B@FHJYCF
M$ZBH#A7Q9D4[@=3#KSKX/[EL]-N9-/N^,DN9I-#7X&TI4>7MKV*W/$+23>6$
M5T,2V$`_[QZ*KKP`]P/,?MY9??9>Q&VMF[8^YXA"WKXLR=^J%M^Z8=J[(\04
M3<,S)NHV08KU%!R(;C"(CKT%O3:^F;ML6X`9@"",M0:GG0^?KS55;0UG\EG(
M.!%?4.T*QYQ_^XNY"<K>2W'SCS8W';'%B(Y5R=;5ISMR2UQSLJ_;VT[7!2Z'
M$$@9R5%J^:PR2PD67*8QS4$*4'5%:UX/Z?H6D2ZI+4Y*'@SF0#@&#S#@K/M-
M_7.H:@VTMC@:UX]*CF5'I]S%#9+9^X9%REXDE5<?S6&[30Q8[$7GH$EF2TH2
MY8N"6[!6*4HUF!*LY*4W<.BN41UV?@+<6<CW6[`TN%.7_-/5<KXGP745)YB<
MIKS_`,`2*^TKR/\`:_XXHY0O#G+B&>R1E8DNU)BYP>QFU]VBG`IMBJF390;M
MRE'P<V:52$HNE$U=Y:4IMZO_`!2MMT:D]\6@5;#"*R`%P)!#:<`12H[/*DMF
M7&VX+9\FJAI+@,M0T\'&O$CDF'<\.1MI<M.6&5N0%D6<XQ[8]XOHAM:=H.TF
M#9Q$04`U&/0(JRC$F[!F9R(`IVRI@(?$1UUNVM)U_3=K6D-^7.:UQQ)<2<`3
MQ'E\RA=SW^BRWS7:>&@YAP`'(]"5=Q^VJCBM/;+@W0#M/*YLR>Z.J6@&5$J\
M(B03C3S[TT@)_JTUYR\6YV-W+7#W;9M?+F>KQV6)I]$HZN4QFG^RU5#?>7B[
M@BO<XY8-+C:G9O)/(3&2AR.B'2,[MX;:@31JB7?*";Q!PV;B4#E$=I]Y?B.K
MUV'<&YV7;1`X9H_])H5.;RMQ;ZFY_,./[SBG2^UE[RV6^$=@QO%6SL-6ODU.
M_LLQJ]FR4G.RT3)L9?(5PLHQZT<-&Q]CKL*/3+E*'B)=0?B;LQMT(-0)<,MN
M:\*$%Q..&'#B%+[4W$8G-MAT!Y\@.U/P^ZFN19Y=G"R`?BD2;1L*_KFDVC=<
M2BS<*JQT4N9(AQ[JR1G+E1/</P#7(>"]D9-:>P##,ZGF85-^(6H-DTYK0:G*
M/WDD/VL=OH2O,S/EP&;%K;_'U:-:[P`00^KWO;*>U(?%/<C%&*-/AKH?'J9]
ML]ME4]T]]".H`C=ZU'>%@B?(US@.'W/4R7W.D\C%>W7%0@&*"EP9]L`-E:&.
MDQ;W*Z7*0M?-4ZJ8C_`-5?X-6=F=T1S.([MM13#&K7X^:B[;Q"NV1Z86<_UM
M55OV.8PTI[H_%`VX@A&W#<TJJ!NJ@@E"*&*;YB;N&K_$=>H?&*;3O_B-W!%3
MO#;8<.-&]JIC8IS[AMI37"<>LKZ+D/R'Q1+Y=D\%L;H%QDV$9JOY"&]*X+VD
M"(@]=;7!O+W46IB^/@`Z\),L#&<_$+TA]37"IJF9Y]F9S+^:X_&UNN"C&0;Q
MK$,S&,)VA'DL0J\I)JI`(E$\:8O;,:E0*(AKLK"W?:6;[MH`N&-+AY6BH]0\
MZ!<^^!C2J<U=MW69Q>Q_#VU#1J<E<+H@-8J-2%(CR9=$3[KF9DU.A@;IJ@(`
M)Q\`IJ"DBU;<<IDG+BWK4D#J,:^=.);AC!4<4S!_RDS=*/5G[*>.R13.'^$B
MX(KN-CJ&KV7IBD$JXAX&,'PZZZC3="TFQA[N^IWSFT%0WB10<:<TQ?JF3'E^
MG:G280Y+MLCN`L7(T<P;3DD46S!P")"Q=QJ@404***E2D'IX&"NN<O='GTHX
M\OU=@ZI:WNVWK:<DW7*=GR/'W+,3<=KE,E".WI)J(.H812.#<=]RPK@2;2^E
M;)__`!4_`OPUT.C]U?QF*7@00?/7[L4SO+-T9SMP\BE1@9AK<<-%S3!?>TE6
M+5Z@<A@$!`X%.<H>-:#T'7!N`#B!P!*GQP'D7O:PLH:$(:$)+\I8WLS,6/;P
MQ;D6*1G['OJ`?6Y=-N+..P$M"2)!2?1[A<JA#%;N$AH:@E'\=;6=VZTF;/;>
MY,TU!'(]>B;R1LF88I`#&[`@]%&`3V(O:O\`3D1'C';G;[":.SZ[+#1,M#`2
MI7U*%,'B`Z[B+Q'WPR$6T>I7`@`P&%*4ITZ+GSM';#I3.ZQA,QXG&O7KU7:7
MV*?:P)79QCM\@CT,9*:FTQ/\]QDWY1/7\=)M\0-_,)[O5KMH/(%G\"2.RMI%
MQ>=/MRXFM:'CZ4Z3`_MT<&^,[E&2PQQMQ7:4VEV5$[A-!-)2>(J@%$G:<E-'
M?N&SSQJJAVC"/CJ)U'<^Z=5:8]1OKB9I^8C[@$_M=O:)9'-:6L3'#A2OWE/2
M`C2@[00,4U*F%0@B8`&H`)C&$P@`^`5H&N7N+5]P:3C,!U'L4Q"/I\8!E\B3
MW)>*,79CMB3LG*MBVED&U9@H)O[=NN,92L<[3`G;[I$G8'*DX(41`%2;%`#H
M!M2>G7VL:0X2Z;-)"YO#*:4K7VGTIE>:9I^H?]]"R2OS?IV*'^\?MY/:[O*6
M6F"8DN2S%53"!(^R+\?P48V1`@)%09LCIR(((BF4/YQ$1Z]/#786_B)O:"(1
MNU"=U*\:<^T`*!EVMH`F+X[.(/-,<<</*C3B?V&/;-P[>5NWM"X;E;AGK6DX
MR9MY>^;T?7`WCY:&=$?1D@BV,#0IW#-VF4Y-^X-P=0$-)7_B%N_4(#;7U_/)
M`X$%II0@\1P1%MS1;>4306K&R`\:XJ1SD5QHPGRWQL[Q%GNSV%_6"ZE(Z95M
MQZNJW;J2,*Y(\C'9_2KHF$[)T0#IB!P#<'4-<M9ZK>:;=LO-/<Z.YC<'-<.(
M<,014'FIZ2TM]0@[J^8)&<*'IYDSO%_LY>W-AO(UGY;QUQ[@;9OZP)DD_:=P
M-9A^JXBYI,QC)OD"*/%$N^4YS?F*(=?#707GB%O+4+=]K>WT\MN]I:YKB*%I
M!!!]W@02%&VVU=N6<WU-M9PLGK7,*UXUZGFI,).*BIF.>QLQ&Q<JT>-5&;R+
MD2(.X]XV<!M6:/6S@#H.$ER`&XIRB4=<=%));SBYMQDG',$@C&N!4[-;6]W!
MW%TQKXJ4H>%.BAYR[[!_MD9?N63N]_A=Y8\M+JJ.)!'&=V.K2C%G"Y^ZLNI'
MMRO&PJF4$?RE(0I1H4H!KO+7Q&WE;M:QE_.(V\L/8N9DV5M0$O%C!F/8?:CM
MQF]E3V^>*&2[;RWBS%4FYR%:RXO;=N>\+K7N5["O!04;"ZCTW!6Q$E3H+G`1
MV&Z#\-:ZKX@;OUBU-C?WLTEFX4+,`#C7'"O'ABE=/VKMVPE^HL[.&.?YA6O3
MKT3S>37$?CIR^LUMC[D1C6WLB6XSD%)B(4E1%"5@)84!;&?0,HW,1W%KBB<2
MG`I^VI0!$HB`4@M%U_6=N3=_H,\EK+2E6>?J#U/I4CJFCZ7K;.ZU:".XB')]
M>SH1T'H47L;]N9[74=)MY(,<7_(H)."N$XJ2R8]=PH`@;N`U,S3:)*JMU*T$
MH*":GQ#70M\2]^,,CFZG<@RM`?0CW@W@#[O`<E#.V+LYX#7:=;D`FF!PKQY\
MTLDM[&7M=2B_?<\7+2;**(IH)-V$U,-B@DG02G,BX>`(K&$/,-3".G,GBMXC
M30BVFU:[=`.#26T'+Y>F"PW8>S&N#VZ=;!PX&COXD_OCMQOPEQ1QNRP_@RT(
MZP<>1KZ0F&UMM7JJR+61EC)C(OP,X55/W'ATR[QWCU`*`&N'U?4M0UF;ZK4G
MNGN#@7.XD8X8`=2NIL8(+*+Z:U:(X`*91PIA]P";=R_]KOA1SFDHRX>0.*&,
MQ=L2S0C&=ZVY**6]=1HMJ=95O'K3+7N'<,RJ.!-L4(8XB!?,`%IJ9T?>&X]&
MM6V6G74L-LUV8-&(!PZBO+JHW4-O:'J#B^^M8I7GFX'MZ'M*;)B+V"?;7PQ?
MUL9*MS&-TSUW6;-,KBMMW=M_.YAO&348L1S&R*306[1(SA@NF!DQ,([1ZT'4
MOJ/B+O'5K<6UY?S.B`I0TK3IPX&J86NU-N6T@?!9Q,>.8K[4[SD][<_#7F9=
M5O7KR,Q1$9&N:TH)W;$"_>RSQJ:(A7KU.1=1B/IW"/Z;N12*H;H(B<`ZTZ:A
M-*W#N'0)N_T>[FMI3S90'$4/$'DGMWM_1-0;DO;:.5G1U?+U6UQ:]O'A_P`,
MKEN*[N-V(XW&\_=D4A"7-(M'LBZ6D8EHX,^09']6NND=%)T85>E!`W6OPT:[
MN/<>Y#WFN7DUU+7`O(KC3H!T`\RWT[0M&THC\MMXX:?+7MZD]3Z4?^5'$OCK
MS!LN)LOD99,9?MEV[,)W/'L)"159LFLJW0412D#*-5DUB*IHJF+7S!0PA3K7
M47I-U?Z1,)M-E?#<#@6\>?4$<SZ2E=1TO3M19DOH62LZ.\W0]@3#,.\'O:HX
MO9C@<J8FQ1#6?D^U%ET8*ZHX]QOV\8JZ2],Z327444:;%TO*<3!2@?#757^X
MMVZU#W&I7DT\+A0AQ;PIPP`Y!05EMS;^GW+9;&UCBF:ZH+0<#Z5(1&8EPDUO
M.>Y&6W$Q*EZR$1)+.[L;/#J)G*O'@@Y44()JIK*M42D,`]``/#7'P.NOKA!*
M]QAJ!3"G%=#W<?&B:[Q"BD[IR3>5]R:!SJ,4Y!\W5<J@38]NF5,Z$$P4I4&[
M5L)/C0IJ:ZO5;ET5JV*,Y6N`![<#[%@1L!K1%.29N.1'(>29+.ETX``61$NX
M4'3:THI2@F04/Y$7CUZEV^E*E-IQ:7QL])S6Q+'BF+>9(X^E8,;'\15/6<7=
M@K&KUACU16WH9R=)FW38FCV[A-,JH%3+]0<;!`SI41H83&'J-=<Q'^9ZC<OF
MFD=(X5(J1A3'[.*3=:VKL',:4TKD]BQCCV7ALA6.D,5'RK[>5-D(IH,9RH'0
M7;"`G[)'I?#:(`/P#70Z)=7.K:@8=4>9X\<'?X2>SF`LQ00P&L+0WR)5<ZF+
MDKC7;U^;!^I1K6WIY<Y0`3B=TNG'RK43``^+A0=X?$2Z;Z;GMMSFS8ZEN7?#
MRQ82/0G#W%X&9*EQ4N$9?#L$118%%(5P]BB`=4I5`0(Z,5(/,-=J91H%?EJ(
MURR-O=98!E:17!+6[W.KF-4;KBY"XKM:2"(E[L2!Z)S)B5@U<OD$CD.8@D5=
M(I"F0Y3%H8!'H.DF6$[X<X``[3CZ%O._*W`T*4FW+P@+LC$Y:WY5O),#T#NH
MJ%%0@T#^\2&ABT$>H"%=,C!*UV4\5@.):#V(P>I3_P".3PKXD_WOS>'X:QW,
MG4K;,?M3=+P-2YI`JMFWM)'`A2E=Q[T0C#D-7RB0J@)[1_A4-2,0MBT8CT%8
M1;[8TH7'60P#P`$U%1(`?#8/K0J4/A^&G[7:>.)'VK7FL[$OCCW)-?CYUO'X
M_P#.ZT,\`-&D9>7%97:.X=M,=Y'$"E`I1%=4/*`!0*>MUCZB'J$+I$P@(@&/
M\B%Z_E%Y(E$/]DA52!_080TD9Q7`BB%R`PF+0<?9-,`@(>5=<Y`"O@0RKA)0
M/]T.NCZAHXTKY4+F%:!3'N2@Z``55.!O+T#_`)T!UL);9^+R,WG6.[S8T7*J
M@`8O["R>)#A0Q!>.!3_H3-("0HC\1``$=*@6#N+F_:CN1T74'?3#8C8.2TR`
M)AVE<.`\QZ`<:E?]:T#62W3FX$M/I1E+<`@3>F42C8>1B5"@E%^NCT`1$!$@
MN3U&H_FK4?Z-:EMD<6Y:>?VH6!.8#B?]A9%,8Q=IA%^HH40_$#.`"M/PKI1C
M;(-H2T'R'VI-S\K@$`*&P*8]R+M#PV.5#AU_M4=EJ-?GI-[;+YA7S^U*-J:4
M60J/_P"?9%`0$*&%THF<O3^0_JS&*'SH(:T9]'&2<PQ[#[5LYF4UZH&*)QW&
MQWD5<0Z5,NHYI7_6>!M$?G\::4[VQ'Q.'H*UIT62]X@`!<>Y-`"CN(45W`D3
M-6M4B#("5$1^.VE?CH[_`$[YA]J*%9$RXB838^R88QQJ8YUG!U*_@H:0$Y0_
M`!T=]IWS#[44*X*&5$H`KC_)QBU```Z[@_AX!^H_/4/PUNR33G&@</05@N+,
M:+(*&.)C#C[)?4`K590"CMZ!Y`=@4!`!^`:U>+`X9AZ#[5LWW\0LE$WY0Q[D
MCIU\JZQ1_CN*]`=-9&VS/?C()\Z4<RC:KL,)CTWXZR.>G@!UE#A7YT,\$!$!
M\!\0'27>M25%UE*)"F*7'N2B`(F$:OG@!4P"!J"5TN8*@/@!1#6KIF@+9O%>
M>]49MVRJTAC^_$V2*!A<G</7PH%1+U_4(HAL,%0#Q#3BWD!/NN'H6LO`I&O\
MUN/2`.2*QXM#I*&3<I*NVJ:I%`&A@.V4.F8PB/3H01'700!Q(!(]'ZU&#&4>
M5*/#3EGRD"X?6[9=Z+6P9!0SMRV669Q1T`()ECJH"J5%RAL#S`4.H:@G1L_,
MQE^*H]93KM6E9MU8[G`?+V/9UPR;4A68RA853TRB9ED5/3D<$04)1-/:/7H/
MCISJ]K(]K`>9'W]J/(O/M>Z\:2,F]C+5M6>D;E203-*%C13;2QG#4YTWJ&\A
MB4(54Q:@`;:A40TLVVEMK',XT%/NP0D=S[+8[5BUH)K;<DQOL\@D*19#>,FD
MJH02@DL<3"JZ,*@T`2=`'J%-.]M/8]TF;'W'>G*L);,^IKLN,%G,Y\%2S94K
M+3(FL;>N#AF1!0Y>H[A4;-BB4PCU'^:NFFU*_G)-,,IQ_P`I6<:+7B-S?A5(
M%>B8G_3GIFPJ?S>HN4RK;;6HT*H>H?#^C2EK_P#<#Y1_I%')$;CX`EL(Y5[3
MN>82&8DTA>P#M0C<Y``5`+^@JF6H*=:^-=*:]<QOF!/'IYDC:RT/1>H[RE@9
ML^68OXSTT@F!B.&+EPFW<)*$$2JF%N\!!197>`[AJ-3:>P5-OFJT-IPH?75;
M7<HI08H]69<%D3[11[8]G7@Z9@84SNX,ZA4#K`(E.51!`[9+J:M1*(_Q'QUS
M4CVB5U0*9CZT[C_IM\@]2.VU;;_]$R!79MIZA]^?N?\`J_EIUV?^YI+O6=G'
M[/TYK='[D!F:`X^87R5FN[4)-W`XYMMY<3]E#%2!^].U.FBW8,2N`%`HR+E4
MB0*K_IIB:IA``U"BWB!J`:GM*5H$E>`\O\J<AO&$SEKCC9N+,?7):K6Y;<DH
M#-*&0[M17DP0>1T-<-MIV=;,>Q7)%N"F<*MI%XD58#`43%`!'<1M'!93HY&X
MXN%](>:EHZ-2D)-O%1JK]^W8)/)%\)2L8M-1T<"K2+Q0BG82)YE`*%`$1#2E
M5BBX2%Q,8E2*3E96.CS3,C])BR.W2+-:3EA166+%L$')P6?.UDT#G332`5!`
M@UT5**!;4E.,HAB\DY5^VC(Q@W.^>RK]=LQC8^.00%=9^_=O%44&C-$A1%91
M0Q2IA\0UA%$6+*R?8.2&:[ZP+^LJ_&C%0&KQ]9-SPUT,F[\H`0[9XI!O9$&X
M&.`B%1+Y1T(RA)[E[DSB#!<_CRV\IY`MFR)'*%PK6]:!KCG8&*;/)!I&/I9Z
M+D\I(1Q&D0@TCU0%T96H+@4FT:TUH8V.-2,5D8"@2U,9QG*L49:*DV$C%/F7
MKHV3CE$W\2\:J=4'+9\V443?)K$ZD,B82*!U+76P`&`0B#<F:\66A.-K7NW*
M6.;6N1Z"*C."N.^;7@9MVDLF46X-8:3DV\@HH]5&B:8I@<P`;:(TZ!:#Q0E*
M1746(H85C)'#N$$BB&PR)QWB2I#'5,90H%K0#"`E$!^.L90L4"32\,TXHL=0
M?WEE+'-GE;2"<6Z"Z+WMN!42DE6S9TC'+)2CYJH5P=%^W4,F`=PJ:Q3#0O43
M*%JZ-CC4\5W.\S8NC+FBK)D<FX\CKRG$6PP]I/[UMIM<TF=VB5RV%I"#(#(.
MDW38P'1.D4Q#E$*5KK;E19:UK>"4`SAQO`1$@$)T,F!3`8]#"4YQ6.4V[MIA
M7:5,!$X@`#36KV-?\7);''BD_8YCQ;(7A_E^WR582]](N'*3NR4;OMEQ=K4R
M(.=S5U!-9A:0;ND>V&],4NX3IN`*ZT[B/I]I6,H2G-C$6(!JU-M+N*)3DH80
MZCM.1,_^BFL=Q'T^TK&5JV>V3Y?Z1T=Q'T^U9RMZ+6<CVRDV`(F,>@%*%3G`
M"B80*8P@F2@!41-TH%/$0ULV)C<0M2QIXINM@\@V]Y\D,Y\>BVZX9.L)6CBN
MZGERFD6[AK/)Y21N1=DV;L")%7:J1A+:/W!,:@]T*=.NMP*++6AO!+G<=PP]
MMLT'DS-Q4"W<O$&:+N8?-8]NLX6*HHFR2<OED6Q72Y$#B4#"-0*:@#36:X46
MQQ%.2)%GYGQ5?TP^M^RLI8ZN^?8D4/(0-JWY:=QR\65N?M.#JQD/)/'Y$T5#
M%`YEB%`#"`!XZ%KE"4I=P*26\IPKY:=S;N$*@0#=ORB<QU1V[0H(UZ==8(J*
M%9``-4E+/.&()2[36(WRUC*0O`RJS(UG,KZMAW<2;MJH[!RU-"H2`RBKTI&Q
MNXW!'N)`D<3@``(CN'%O!!:#Q6](83Q),219F3QQ9SZ3[O?*_5A&2ZIE`&I5
M14.D-#UZ[O'3EM_=,%`\T\U?3Q20MH,^8C'RE'A6!8!#N89HS09L%(]PQ39M
MB%0:))K(G3`I$$]J90`1"E`TC'<O;*)FD]X"#7CZUL8F<A@HV.*TJK968[EL
M"0W-S2!58DQ0'L)J2<&HNHDJ)"T*/>9*"0"^`B(#XZZ.Y%U<V1FF.;(*\!]W
M2M4U`]Z@1>OE.8X]Y^-<S-I2$>/W\NQ`JAB*24%,G+]6CQ.-04<MUA%0@FJ<
M!*`>'32L5RZ]MNXD(+2.':`FT@G8[`X>9/2:Y`P!>[5E>SV0LU1\R125.[F$
M6H346L4`$J:A5D07,J4?['EKJ*=;:I:/<+-Q8#S%*$'CQ-1A@GD$ENYG\P5?
M3[O0F5\@,H'S3>-NV=9*2[R'C)-1BQ(8#$7EY=ZF*(O&28?WK9!$1H`U('C3
M72:-%;Z;";R;_N3SJ<.(I3$>=-<Q.`2X\CE&>.,"6IC1!R0KI\>*C52@.\ZX
M1XE</UA`U1(1Q(!NZ4`/`.G33+16.O=9-[_Z@Y_Y2/4%DN=1+%Q;MQ6W\/6L
M+@AVZDF:0F3MPW$$$WBYQ:D,4*?E2Z_CXZY^^F?-,YS\7#"O!/66\+![H-#V
ME*7<6'\778_+*W)8=L3DB4`VO)**;.7`!X]5%"B(]1TR.JZA"WNXGT;Y`?6%
MLZVA>/>%?.CM%0<1!LD8Z&CFD6P0(1-)FP1(U;$(0@$*4$4@*2A2A3P\-'>R
M/&9YJXX\%N&-:*`8!>GVR?V0\*?T?+^&C,[JLY0DIR;#X_NNR+NMK*[>WW..
MKJBI"V+M:76Y;,H.1@I9(S59FY=.E4$P2>`KM"IBB0U!`0$-:K*C8X_W5=/$
MSD_9G!8E_DS/@K)>.+POOC])NYEK-9+P/#X\+$GE,<7O)ME'3BY;.>1LZ@G;
MDFX,1P0J/IQ$Y2@("$Z3GAAB2SKQ>R-:]KI$_P`R;8+$Y5Q8ON61]+EG%4E&
MWY9#,%$E$U$2SCN%)'*B(B7L.C@8!`1T(30<#9(A/<0Y%8CS?"G=/L.\5L:,
MIY@!P7292/)[*]KLQG&ZH_HF5>XOMHO8.FH4Q6TDY6Z`>H:$)[7,;"\;R+X\
MY"PC)7V7'"E^1J#"*N99R@F1G+MU$W[-&12=*H(2T2_<-P(]:&.'J6PG*4!$
M0#0A)-P2R^SR!%9?QS<&+L>8SS%@*\HS'^8XO$Z$?_ES<LQ^WFLK;EW6M(QC
M=O\`X"X;;.@X&/<"9U&&,1%6IJB(A)ESNMC&EU\JO;;CLA0-IRC1WFS**O>N
MIA%NFSLL+B"YE0A#C*$,@9J=X_%R0@5`RC<*5T(4G<5%P\7'1\;`L&3"-:@7
MT$9'III1[5-`A=B34$![#;M)C^EL\GA3IH0JZO&'#61N0>.^3\K<65>-I+OO
M?.>;;9S-&Y;Q\E<&4+$6BYR0B;4M]W+OGB#J*9VY:IF3V,]."2&YP8Y3"81H
M(4[G'+',]B3!&*\87%>BF29W']DPEMR=^&2%!2ZUHV.*@G+E*95P857:`)B*
M@J'$X^81$1T(47N!L!81OS.GNOYLR#8MM7_(R.875BBTN,AIQE%0-CX&M=G+
M1S!B^,JSA74PZ56.NX;D(L<HD\WE#0A,X@\$8:@O97PG>:$%&/,CW/+8RN*#
MR?..'4E>;6[)[+J;.(49W8[.>92)'PR16"*!5023;D`NVFA"LS+BFU17%51-
M%%/>H=0:@=)LB0-PB8:[Q3*GNJ/6@A\M"%#IQU@(CA]R4@<`W%"8[R%;/(Z^
M,RY=X^9VB_H4OE"/GYUZ\ON_,7Y)%$74S+-VC"065A+A05!NH@S%JL!1(F`B
M%,5$2D0]7D&49(QSQ:+6(V?H,G[9VNS<"7?VGZ*"JBC-P8!J!%`*82T&FA"]
MW0A:SLI#('*H!!3$2`H!_P`NP3E`WRZT'I^.A"C:XUF1=^X'[C;PBC5=2,;\
M7+<>KHC1T@Y:8I7GC,W)0#RE*RN!%9,`Z`"XAH0BQ[I]CVYEVS>)6&KL.M]#
MR)SAP6TDVS=\ZCG$G$6_^YIQW'E<,SI+@F_!J5-0H&`%4A,0:@8="%X?)O"V
M*\=<H?;IFL9V-:6.[Q6SI=-JA*6G$-H&3D\?(8NN!_<-OO#QQ$/J4:LBU3.<
M''<$BA2G`0,&A">-S3N"];,XB<F+IQL:0)?]O82R;-VFM&I^IF&4PSMJ2>-G
MT4EM,9:19*D*JV3`.JI"@&A"2#AIB/BO`<?N/3S%\1C:?39V=;T_&7:9.)>W
ME-7@^A!-=%SO)=4RT^YO.3>/72DGW%#',LHH`@'@`A/?5N&,:S<=;QY:+0EI
M%NH\90IW;5.8>QR!@*J[91IEP768-#F`JRI2&[8T`=:25R&G&BR.*,PC0AAK
M2A:U`*TZ5Z!\=(P&C_>0_@HN^3MI2V-LI0V4+=`Z+&;DB.DGI!'9%W%%;'1V
M[PH]%$ID$NT4IN@";7?:7<-FLG6C_P"L6%OI%`F!<&29S\(-?0G*(!8'*O'+
M8KDZ3>X&J).X!!`DG!21"CO4(0*'.S55"HE_+341)%/I4U9`>Z/K]OK2_>1W
M(JU-AD>%V1TGYO23%N234PB7ZBX4,V63;^``=L6A3"!1J(CUU*0:Y:%M)`:^
M11<]O(U]6\*IQN*\#V5A*.<WO>$VW?S#-D8/K2PBWCH-N(5,$00]1!SUIW`#
M=0::C+V\DOI>YMP0T\N9\O1+M&7%-.N.:D^2^9(UG'(K)P(OC-&20A19G;31
MQWG$TY)T[!W!ORB-!H--3D##H$'U$W3TT\OE6G$]BEEC8MG%L&,<S)VVL>V;
MM6Q`'H5)LF"28#\_+X_,=<*Z3.2>I/VJ7HO0IINYA)6:KEI8"@HL(:RA$>_<
M:V+E&UY6R<A6Q%W=:<V@5M*P,TB+E@]2(?>0%2;BJ`)3>`E,40T(298EXI<>
ML$RDM.8EQ=;UESDZDDVE9QCZY]-O&*(I"G&&F9AY)2B<2F5$A2-2*E;I%*`)
MD+H0M+D'?.<+%M<7&",+DS-=T@G*,T6;J]K8L:.MY\""7T.;GUKB=MA>VPBX
M.)'Q69%GQ42`*21]_00BIPEXS,N*W'VTL8'7BWUT.EIN\\E3D0T.P871DN^)
M-S<-ZSC5HLFDLV8N9A\?TZ1B@*20``4#IH0ETR3B+'>8+3<6/DNV&=UVN[>,
M9!>*=KOVJ9GL:L5PR=)N8YVS?-UFRY0.0R:I1`P5T(6GBK".*\(0*ULXILR*
MLJ#=/EY5\SBP755DY1V)1=RDO(OUGDI,23HJ9"G7=+K*B1,I0,!0IH0M#+_'
MW#N?8F+A,PV+$WW&P4A]6@T947:"\)+"U78J2<1(1CAA)1KQ9DX,D<R*Q`.F
M-!#0A*7#0,9;\4PA(E$S6,BVJ#*.;=U17TC-JD5!NV366,HNH1%$H%`5#'.(
M>)A'KH0FZ7[PJXNY.O%_?][8>MJ6NZ739DG)IN>3@W-P#'"(L%;A"WW\4G/+
M-"&$A#.RK#L&@UZ4$)RK",8Q;1LPCVY&;)F@W;-&J%2(-FS1))!N@BG42II)
M(HE(!0H%`_CH0BC#8PL*WAO+Z';$9%$R'+R,]?*;-'MDNJ9E6*$8^DI@*B9P
MZ7CVQ$A,`E\A:4T(7@FP1B$^.X'$JE@V^?&UKK1;FW[.,U'Z+%.(5^:3BUVC
M<#@)%&+\PJICN&A^NA"4]=B@Y)VU@.</U.HF\U%2G34"M*"!TE!(-?Y1IH0F
MZXZXB<<<.W.O>V,\36[;%X+-7C)O<Q!E)J2AF;U1%5VR@CSTC*?MZ.>'2#NH
M1X-DCEJ`EH8:B%Z>!..]DX$/E.1MI21D[DS-DVX<KY!N:8='=R4Y<MP*%`J0
M"!$6K*(@X])-FP:HID(W:I%*.\^XYA"<'H0NI5$BQ0*H&XH#42_RFZ"`;@^-
M!&H?B&A")\)CFR;<N2\KP@[=CXRZ,A.(AY>\ZU2%.0NAW`Q+2"AW,LKN$'"T
M?#L4FZ8T"B1`#0A<KHQ[9EZO+6D+KM^/G7MDW`WNJU'3]+NJP-Q,TET&DQ'F
M`2]IZU2<J%(;K0#CTT(7.:L"S[CGK1NB=@6,I<-A/)"0LZ7>$%1Y;[Z68*Q<
MFZCE-P`DL^CESH*#0:IF$.FA",+N-;/4'#=P45$G2*B"Q3`F<ITU0(!BF34(
M=)0H@0*E,4Q#`(@("`B&A";I9O#;C)CR^TLEV-B&W;5O-L[D7[22A7$TR9,'
MLMW/J;J.MY.4"VXY9[WC]P4&:=0,(>`Z$)8'F,K"D+Y@LF/;6B7-^VQ"R5NV
M]=2K8IY>'@IA5->4BV+@1_1:/UDBF4"E1$/$-"."/-.E/PI^.M<HK5!Q1*OB
MQ8&^[9E;;G4!79OVX@53:4ZS1TF0W8?M_+T=(G$!K\:4T^M+R:UG9+'3,UP.
M/`T-:'L3::%KHGC&I:?4HI+NL#*O'RY%9B)/+MH@ZX@SNB'`SIJ=$#?HHRZ2
M93;3&Z`8NVM-=>VXM=9']^:'F&T;[>I4-!]3;BC!Z02CNSYH9/;LRHNXFU9!
M<B.PTBJWD&JBHE*(`=5L9(*C\1\`UD;;VXUP.>?_`-P>Q.775Z[BUO\`LI-9
M*ZLQ<@YQG%E4<SY#FWDCHQLHQMYE7X.E=PHN"%_[M*3Z;H>FR&YM7/+QC[SP
MX=.%$G$^1YHY2+X.P5&XI@U3NUR25W2W;+,S292D$R!!*/HFQ#%-V&=2]2@(
MU^>N2W%K5WJK!`_*(A\HR\:<<>Q2D4##\5:IQ@``4_#44&@4*<K.MD(:$(:$
M(:$(:$+Q"^DWNZ^H[>];N][L]K;N_P`5_>CWNSO_`.)TI^3RZ$+T4-G92W;_
M`,A=O<[>ZG6G]S^E6G]GIH0MH/`*>'PT(0T(0T(0T(0T(0T(0T(0T(0T(72I
MMWIUW[_-LV5_#=N_DI3YZ$+M"E1I7X5^5>OA\*_/0A9T(0T(0T(0T(0T(0T(
M0T(0T(0T(7!2G;/7=38:NVNZFT:[:==WRIH1ASX+Q)/Z3Z1Q]5])Z'8'J/7>
MG]%V^F_N^K_POY:[MWFI72L7U6;^77-3MK]F*Q_)[/L3=IG_`/E#ZH;ZI_EA
M]3W==OTWQKTIV`[/YOEI\W\TI[V?LXK4]Q0\.'8EIM']B_32_LSZ%].IYOHG
MHZ>`?WOIOU:Z1F^OK_.KY\U/8F,?=?A1U'9M)^?9UKMVT_VZ>;^K3&6F.=2#
/.SBMG65E#0A#0A#0A?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
